For the Inventor, By the Inventor

Enter assignee name

Centaurus Biopharma Co., Ltd.

USPTO Granted Patents = 33

% Expired Patents = 21.2

CIPO Patents = 2

EPO Patents = 26

Forward Citations = 57

Loading Chart...

Loading Chart...

105 inventors (with patents filed for the assignee):

Yongxin Han (17 out of 21 patents)

Yong Peng (14 out of 26 patents)

Yuandong Hu (14 out of 15 patents)

4. Hong Luo (13 out of 17 patents)

5. Dengming Xiao (12 out of 14 patents)

6. Xiquan Zhang (10 out of 47 patents)

7. Xijie Liu (9 out of 10 patents)

8. Li Zhu (8 out of 42 patents)

9. Fei Liu (8 out of 18 patents)

10. Hongjiang Xu (8 out of 31 patents)

11. Hui Zhang (7 out of 123 patents)

12. Na Zhao (6 out of 27 patents)

13. Rui Zhao (6 out of 16 patents)

14. Yinghui Sun (6 out of 10 patents)

15. Aiming Zhang (5 out of 14 patents)

Core Competencies:

Pharmaceutical Composition

Kinase Inhibitor

Neurotrophic Factor

DPP-IV Inhibitor

Pyrrolopyrimidine

Triazine Derivative

Quinazoline Derivative

Amino Pyrazole

Sultam Compound

Heterocyclic Compounds

Antitumor Compound

Selective Estrogen Receptor Modulators

33 patents: Sort by Forward Citations

1. 12097204 - Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof (2024-09-24),

2. 11773079 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine (2023-10-03),

3. 11254665 - Crystalline sulfamide compound (2022-02-22),

4. 11203586 - Iridinesulfonamide compound and use method thereof (2021-12-21),

5. 11111240 - Sultam compound and application method thereof (2021-09-07),

6. 11098060 - Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof (2021-08-24),

7. 11021464 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt (2021-06-01),

8. 10858340 - Crystal of salt of quinazoline derivative (2020-12-08),

9. 10829492 - Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor (2020-11-10),

10. 10822319 - Crystal of DPP-IV long-acting inhibitor and salt (2020-11-03),

11. 10766901 - Preparation method for chiral pyrrolopyrimidine compound (2020-09-08),

12. 10745383 - 1,3,5-triazine derivative and method of using same (2020-08-18),

13. 10626118 - Pyrrolopyrimidine crystal for preparing JAK inhibitor (2020-04-21),

14. 10617692 - Pyrrolopyrimidine comprising cyclopentyl substituent (2020-04-14),

15. 10570141 - Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof (2020-02-25),

Company Overview

Centaurus Biopharma Co., Ltd. is a biotechnology company based in Beijing, specializing in the development of innovative therapies for various diseases. The organization focuses on research in biopharmaceuticals, particularly in the fields of oncology and autoimmune disorders. By leveraging advanced technologies and scientific expertise, Centaurus aims to address unmet medical needs and improve patient outcomes through novel treatment solutions. The company's commitment to research and development positions it as a key player in the biopharma landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

33 Patents

#132 in Beijing

#946 in China

#20,162 in the World

Centaurus Biopharma Co., Ltd.

Forward Citations = 57

105 inventors:

Yongxin Han (17 out of 21 patents)

Yong Peng (14 out of 26 patents)

Yuandong Hu (14 out of 15 patents)

4. Hong Luo (13 out of 17 patents)

5. Dengming Xiao (12 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Centaurus Biopharma Co., Ltd.. Retrieved from https://idiyas.com/company/centaurus-biopharma-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…